Hot off the press! The 1Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!
The 1Q10 OnBioVC Trend Analysis tracked, in aggregate, 74 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,260.1M. Compared to 1Q09 OnBioVC data, this investment activity represents a decrease in the number [...]

• 713http://clsdf.com/2010/04/1q10-onbiovc-trend-analysis-now-available/1Q10+OnBioVC+%7C+Trend+Analysis+Now+Available+2010-04-26+03%3A19%3A55admin

So based upon the recent ruling of Myriad Genetics (NASDAQ: MYGN) invalidation of certain patents covering the BRCA1 and BRCA2 genes, I was planning on levering the news as fodder for an all out April Fools’ post effort, likely to have been something along the lines of ‘10,000 Gene-based Patents Overturned, Biotechnology Industry Implodes’. [...]

• 709http://clsdf.com/2010/04/myriad-genetics-an-april-fools%e2%80%99-that-wasn%e2%80%99t/Myriad+Genetics+%7C+An+April+Fools%E2%80%99+that+Wasn%E2%80%99t2010-04-05+02%3A21%3A58admin